A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer

BACKGROUND: Only a small proportion of patients respond to anti-VEGF therapy, pressing the need for a reliable biomarker that can identify patients who will benefit. We studied the biological activity of anti-VEGF antibodies in patients' blood during anti-VEGF therapy by using the Ba/F3-VEGFR2...

Descripción completa

Detalles Bibliográficos
Autores principales: Wentink, Madelon Q, Broxterman, Henk J, Lam, Siu W, Boven, Epie, Walraven, Maudy, Griffioen, Arjan W, Pili, Roberto, van der Vliet, Hans J, de Gruijl, Tanja D, Verheul, Henk M W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061906/
https://www.ncbi.nlm.nih.gov/pubmed/27575850
http://dx.doi.org/10.1038/bjc.2016.275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061906/
https://www.ncbi.nlm.nih.gov/pubmed/27575850
http://dx.doi.org/10.1038/bjc.2016.275

Ejemplares similares